Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6–11 Years) With Moderate-To-Severe Asthma And High Eosinophils

Abstract

Children with moderate-to-severe asthma often remain symptomatic despite standard-of-care treatments, and patients with elevated eosinophil levels frequently have increased rates of exacerbations and worse asthma control. In the phase 3 LIBERTY ASTHMA VOYAGE study (NCT02948959), treatment with dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, was generally well tolerated and resulted in fewer exacerbations and improved lung function vs placebo in children aged 6–11 years with uncontrolled moderate-to-severe asthma.